Welcome to our dedicated page for Immunome SEC filings (Ticker: IMNM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Immunome, Inc. filings document the company’s targeted oncology business, public-company governance, capital structure, and material event disclosures. Its 8-K reports cover operating results, business updates, clinical and regulatory communications for programs such as varegacestat and IM-1021, investor presentations, and equity financing activity involving its common stock.
Proxy materials describe board matters, stockholder voting items, executive compensation, equity plans, and governance practices. The filing record also reflects Nasdaq-listed common stock, stock-based compensation arrangements, and formal disclosures tied to the development of antibody-drug conjugates, gamma secretase inhibition, and FAP-targeted radiotherapy within Immunome’s oncology pipeline.
Immunome Inc. Chief Medical Officer Robert Lechleider exercised options and sold shares of common stock. He exercised 55,000 shares at $8.73 per share through an employee stock option, then sold 55,000 shares in open-market transactions at weighted average prices of $19.56 and $20.66.
The sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 26, 2026. After these transactions, he directly holds 15,805 shares of common stock and 345,000 employee stock options, which vest over time and expire on October 26, 2033.
Immunome Inc. Chief Financial Officer Max Rosett reported an exercise-and-sale transaction in company stock. He exercised stock options covering 60,000 shares of common stock at an exercise price of $1.05 per share and, on the same date, sold 60,000 shares of common stock in open-market transactions.
The weighted average sale price was $18.23 per share, with individual trade prices ranging from $17.95 to $18.66. These sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025. Following the transactions, Rosett directly holds 54,037 shares of Immunome common stock, and the exercised option is now fully vested and fully exercised.
IMNM reported a proposed sale of 60,000 shares of common stock by means of a stock option exercise to occur on 06/15/2026 for cash. The filing notes a prior sale by Max Rosett of 65,000 shares on 04/02/2026 for $1,425,084.64.
The filing lists transaction mechanics as an issuer-related stock option exercise and records broker information for Fidelity Brokerage Services LLC. It is a routine Section 144 resale notice reporting planned insider-related dispositions.
Immunome Inc. director Sandra M. Swain received a grant of stock options covering 9,897 shares of common stock. The options have an exercise price of $18.16 per share and expire on June 9, 2036.
The award vests in four equal quarterly installments starting on June 10, 2026, with additional vesting on the same day of each succeeding fiscal quarter until the one-year anniversary, as long as she continues serving with the company on each vesting date. Following this grant, she holds options for 9,897 shares directly.
Immunome Inc. director Philip Wagenheim received a grant of 9,897 director stock options, each giving the right to buy common stock at an exercise price of $18.16 per share. These options expire on June 9, 2036 and are reported as directly owned.
The option vests in four equal quarterly installments starting on June 10, 2026, with additional vesting dates on the same day of each succeeding fiscal quarter over the following year, conditioned on his continued service with the company at each vesting date.
Immunome Inc. director Jean Jacques Bienaimé received a new stock option grant covering 9,897 shares of common stock. The option has an exercise price of $18.16 per share and expires on June 9, 2036. Following this grant, he holds options for 9,897 shares directly.
The option vests in four equal quarterly installments, beginning on June 10, 2026 and continuing on the same day of each succeeding fiscal quarter for one year, subject to his continued service with the company on each vesting date.
Immunome Inc. reported a Form 4 insider transaction involving stock options linked to director James P. Boylan’s board service. A director stock option covering 9,897 shares of common stock was granted with an exercise price of $18.16 per share and an expiration date of June 9, 2036.
Mr. Boylan has agreed to receive and hold these securities for the benefit of Enavate Sciences, LP and disclaims beneficial ownership and all right, title, and interest in them. The option vests in four equal quarterly installments starting on June 10, 2026, conditioned on his continuous service with the company on each vesting date, and results in a total of 9,897 derivative securities held after the award.
Immunome Inc. director-related entity receives new stock option grant. A director stock option covering 9,897 shares of Immunome common stock was granted at an exercise price of $18.16 per share, expiring on June 9, 2036. The filing lists director Isaac Barchas as reporting person, but he has agreed that any securities granted for his board service are held for the benefit of Arsenal Bridge Ventures, and he disclaims beneficial ownership and all rights in the reported securities.
The option vests in four equal quarterly installments starting on June 10, 2026, through the one-year anniversary, with each vesting date tied to continued service with Immunome. After this award, the reported derivative position in these options is 9,897 units.
Immunome Inc. director Carol Schafer received a grant of stock options as part of her compensation. She was awarded options covering 9,897 shares of common stock at an exercise price of $18.16 per share, expiring on June 9, 2036.
The options vest in four equal quarterly installments starting on June 10, 2026, continuing on the same day of each succeeding fiscal quarter for one year, as long as she remains in continuous service with the company. Following this grant, she directly holds options for 9,897 shares.